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Abstract24
Immune evasion is a critical survival mechanism for bacterial colonization of deeper tissues and25
may lead to life-threatening conditions such as endotoxemia and sepsis. Understanding these26
immune evasion pathways would be an important step for the development of novel anti-27
microbial therapeutics.28
Here, we report a hitherto unknown mechanisms by which Salmonella exploits an anti-29
inflammatory pathway in human immune cells to obtain survival advantage. We show that30
Salmonella enterica serovar Typhimurium strain 4/74 significantly (P <0.05) increased31
expression of mRNA and surface protein of the type 1 receptor (VPAC1) for anti-inflammatory32
vasoactive intestinal peptide (VIP) in human monocytes.33
However, we also show that S. Typhimurium induced retrograde recycling of VPAC1 from early34
endosomes to Rab11a-containing sorting endosomes, associated with the Golgi apparatus, and35
anterograde trafficking via Rab3a and calmodulin 1. Expression of Rab3a and calmodulin 1 were36
significantly increased by S. Typhimurium infection and W-7 (calmodulin antagonist) decreased37
VPAC1 expression on the cell membrane while CALP-1 (calmodulin agonist) increased VPAC138
expression (P < 0.05). When infected monocytes were co-cultured with VIP, a significantly39
higher number of S. Typhimurium were recovered from these monocytes, compared to S.40
Typhimurium recovered from monocytes cultured only in cell media.41
We conclude that S. Typhimurium infection exploits host VPAC1/VIP to gain survival42
advantage in human monocytes.43
44
45
46
Introduction47
Survival of some Salmonella serovars in innate immune cells is a critical step for immune48
evasion and colonization of deeper tissue, which may lead to life-threatening diseases such as49
Gram negative sepsis or typhoid. Understanding the pathways associated with immune evasion50
and survival may inform better therapeutic strategies for the treatment of such diseases.51
The bi-phasic model for human sepsis proposes a phase of uncontrolled production of52
inflammatory mediators, which leads to systemic inflammatory response syndrome (SIRS)53
followed by a compensatory anti-inflammatory response syndrome (CARS) (1-3). The SIRS54
(acute) phase of sepsis is associated with high systemic concentrations of pro-inflammatory55
cytokines released by monocytes and macrophages, such as TNF-α, IL-1 and IL-6 (4). 56
Intervention with anti-inflammatories has been proposed as a rational therapeutic avenue during57
SIRS but specific inhibition of IL-1β or TNF-α has failed (5), while broad ranging anti-58
inflammatories, such as glucocorticoids, are also widely used in the treatment of sepsis but their59
effect is debateable, probably due to timing of therapy, dosage and the development of steroid60
resistance by glucocorticoid receptors (6).61
Studies, to date, have indicated that vasoactive intestinal peptide (VIP) may have therapeutic62
potential in the treatment of sepsis. The amino acid structure of VIP is highly conserved63
throughout the vertebrates and is identical in all mammals apart from guinea pigs (7). In murine64
models of LPS-induced sepsis, intra-peritoneal administration of low concentrations of VIP (<565
nmol) prevented mortality and this was associated with inhibition of inflammatory cytokines (8).66
VIP exerts its biological effect via three G-protein coupled receptors; VIP receptor 1 (VPAC1),67
VPAC2 and a receptor which is also activated via the pituitary adenylate-cyclase activating68
polypeptide (PAC1). VPAC1 is constitutively expressed by some resting immune cells (9-10)69
and the immunosuppressive action of VIP on LPS-stimulated murine macrophages occurs via70
this receptor (11). Increased VPAC1 expression was also reported in human peripheral blood71
monocytes following intravenous administration of LPS and correlates with increased VIP72
concentration in sera (12). However, using virulent S. Typhimurium (rather than LPS) we have73
shown that VIP promotes survival of S. Typhimurium within human monocytes, which is74
associated with inhibition of proinflammatory cytokines and increased survival of the infected75
cells (13). This may indicate that S. Typhimurium increases receptivity of monocytes to VIP,76
specifically to inhibit production of inflammatory mediators, thus gaining survival advantage. It77
is known that upon activation, VPAC1 is internalized and may be recycled back to the cell78
membrane (14-16) but nothing is known about the intracellular pathways utilized to achieve this79
and nothing has been reported regarding the effect of Salmonella infection on VPAC1 or these80
pathways.81
The aim of this current study was to investigate whether S. Typhimurium induces VPAC182
expression in human monocytes, and, if so, to determine the intracellular pathways responsible83
for this.84
85
Material and methods86
Reagents87
Unless otherwise stated all reagents were purchased from Sigma-Aldrich, Poole, Dorset UK.88
PCR and microarray reagents were purchased from Qiagen, Manchester, UK.89
Bioethics90
Human blood used in this study was obtained with patient consent. All studies were conducted91
following approval by local ethics committees. Studies were performed on 5 separate occasions,92
therefore blood from 5 individual humans.93
Bacterial culture and strains.94
S. Typhimurium 4/74 (17) were grown in Luria-Bertani (LB) broth (Life Technologies Ltd.,95
Paisley, United Kingdom) for 18 h at 37°C under agitation. The bacteria were then sub-cultured96
in fresh LB broth for 4 h to late log phase (established by conventional counts of CFU). Prior to97
incubation with monocytes, bacteria were adjusted to a multiplicity of infection (MOI) of 10.98
Isolation of peripheral blood monocytes (PBM)99
Human blood was purchased from the blood transfusion service (Sheffield, UK). The blood was100
diluted with sterile PBS then gently poured onto Histopaque-1077, prior to isolation of the buffy101
coat, as standard procedure. After appropriate washing steps, buffy coat supernatants were102
resuspended with appropriate amounts of cold MACS buffer and anti-CD14 antibody coated103
micromagnetic beads (Miltenyi Biotech, Bisley, Surrey UK) according to the manufacturer’s104
instructions. The viability of isolated monocytes was assessed using Trypan blue (10% v/v) and105
was found to be > 90 % prior to use.106
Salmonella invasion assays107
Monocytes were firstly washed with sterile PBS prior to culture with S. Typhimurium 4/74 at a108
multiplicity of infection (MOI) of 10:1 at 37 0C and 5% CO2 for 60 min with or without109
VIP (10-7 M). The cells were then washed and cultured with RPMI media containing 100 μg/ml 110
gentamycin and incubated for a further 60 min. The monocytes were washed and the media was111
substituted with RPMI containing 25 μg/ml of gentamycin for a further 2, 6 or 24 h post-112
infection (pi) in total. The cells were then washed three times with PBS at room temperature and113
then lysed using 1 % Triton X (Fisher Scientific LTD, Loughborough, UK) for 15 minutes at 37114
0C. Intracellular bacterial counts were determined by serial dilution at different time points of 2,115
6 and 24h pi. Viable bacterial cell counts were measured as colony forming units per ml116
(CFU/ml). All counts were performed in triplicate on 5 separate occasions.117
PCR analysis118
RNA was purified from treated or control monocytes by standard methods, using Rneasy plus119
kits (Qiagen, Hilden, Germany). RNA quantity and quality were measured using a NanoDrop120
8000 spectrophotometer (Thermo Scientific, Warrington, UK) and was converted into121
complimentary DNA (cDNA) using a SuperScipt first strand DNA synthesis kit (Invitrogen,122
Carlbad, CA, USA). For quantitative PCR analysis primers and probes were designed using a123
universal probe library (Roche Diagnostics, Mannheim, Germany). A PCR reaction volume (20124
μl) consisting of 10 μl Light Cycler 480 Probes Master (Roche, Germany), 1 μm of each forward 125
and reverse primer (Eurofins MWG, Operon, Germany) and 0.2 μl, labelled with Fluorescein and 126
dark quencher dye. The total volume was adjusted to 20 μl using PCR water.  In negative control 127
wells, PCR water was added instead of cDNA. Standard curves of target and reference genes128
were performed at dilution ranges between 1:10- 105. Thermal cycles consisted of denaturing at129
95 0C for 10 min and 40 cycles of sample amplification at 95 0C for 10 secs, 60 0C for 30 secs,130
72 0C for 1 min and cooling at 40 0C for 30 secs, performed using a Roche applied sciences light131
cycler 480 (Roche, Germany). All data was normalised to unstimulated monocytes, or expression132
in uninfected mouse tissues for in vivo studies, and quantification was determined by comparison133
to the reference gene using the Pfaffl method (18). All primers and probes used in PCR are134
shown in Table 1.135
Immunofluorescence studies136
Freshly isolated monocytes (5 x 105) were cultured on glass cover slips (VWR International Ltd,137
Leighton Buzzard, UK) placed in 24 well culture dishes, for 6h. The monocytes were then138
infected with S. Typhimurium (6h pi) or cultured with VIP (10-7 M) in RPMI media for 6h, or139
cultured for 6 h in RPMI media without bacteria or VIP (uninfected control). After 6h the140
monocytes were washed 3 times in PBS and fixed in paraformaldehyde (4% v/v) for 10 min at141
room temperature prior to permeabilization in Triton-X (Fisher Scientific, Loughborough, UK)142
(0.2% v/v) for 10 min. After washing 3 times in PBS, the monocytes were incubated at room143
temperature for 30 min in blocking buffer; bovine serum albumin (BSA) solution (3% w/v in144
PBS). After washing 3 times in PBS the monocytes were incubated for 60 min with appropriate145
primary antibody (300 μl), washed 3 times in PBS and incubated with secondary antibody (300 146
μl) in the dark for 45 min on an end-to-end shaker. After a final washing step, the coverslips 147
were placed onto microscope slides prior to adding Vectashield hard set mounting medium. All148
slides were examined using a TCS SP2 confocal microscope (Leica Micosystems, Heidelburg,149
Germany). Each panel shown in figures 3 and 4 are merged plane image captures 4 μm below the 150
cell surface. To prevent spectral overlap, Alexa 488 and Alexa 647 fluorophore conjugates were151
chosen and bypass filtering was applied to prevent bleed through. Laser intensity and detector152
gain were optimised and standardised throughout. Each experiment was repeated in triplicate on153
5 separate occasions. All primary and secondary antibodies used during the confocal analysis,154
together with suppliers are shown in Table 2.155
Flow cytometry156
S. Typhimurium infected monocytes (6h pi), monocytes cultured with VIP and monocytes157
cultured only in RPMI media (unstimulated controls) for 6h were centrifuged at 300 x g for 10158
min. The supernatant was discarded and the cell pellet was washed 3 times by resuspension in159
PBS and centrifugation at 300 x g for 10 min, repeated a further 2 times. Monocytes were either160
left non-permeabilised or permeabilised for 10 min in Triton-X (Fisher Scientific, UK) (0.2%161
v/v) and washed a further 3 times prior to incubation at room temperature for 30 min in blocking162
buffer (PBS and BSA 3% w/v). After washing 3 times in PBS the monocytes were incubated for163
60 min with mouse anti-human VPAC1 IgG2a (300 μl), washed 3 times in PBS and incubated 164
with rat anti-mouse IgG2a-Alexa-488 (300 μl) (Table 2) in the dark for 45 min on an end-to-end 165
shaker. The monocytes were then washed 3 times prior to analysing antibody fluorescence using166
a FACScan flow cytometer (Becton Dickinson, NJ, USA). Gating of the cell populations were167
performed, according to journal guidelines, using CD14 expression (92% of the population) and168
side scatter (SSC). In FACS plots, quadrants were set according to fluorescence expressed by169
monocytes incubated only with secondary antibody (control) (lower left quadrant) and170
fluorescence in test cell populations were compared to these. Data analysis was performed using171
FACSDiva software (Becton Dickinson, USA). Each experiment was performed in triplicate on172
5 separate occasions.173
Calmodulin 1 (CAM1) agonist and antagonist studies174
To investigate the effect of CAM1 on VPAC1 expression, freshly isolated monocytes (5 x 105)175
were incubated for 2h with either the CAM1 agonist; calcium-like peptide 1 (CALP1) (20 μM) 176
(Tocris Bioscience, Abingdon, UK) or the CAM1 antagonist; W-7 (30 μM) (Sigma-Aldrich, 177
Poole, UK). The concentrations of agonist and antagonist chosen in these experiments were178
determined via dose response and output curves (data not shown). PCR and flow cytometry179
were then performed to assess VPAC1 expression in S. Typhimurium infected and uninfected180
monocytes, as stated above at 6h pi. Mean data was obtained from experiments performed in181
triplicate on 5 separate occasions.182
Statistical Analysis183
Two-tailed unpaired student's t test or one-way ANOVA were performed to determine184
significant differences between different groups (control negative, S. Typhimurium infected,185
with or without VIP) using Graph Pad Prism software. Bonferroni's multiple comparisons test186
was applied to examine significant difference between the means of more than two groups,187
following ANOVA. Significance values were determined at the 95% confidence limit (P < 0.05).188
189
190
Results191
S. Typhimurium increases VPAC1 expression192
High constitutive expression of VPAC1 was detected by RTPCR but following S. Typhimurium193
infection, expression of VPAC1 increased further (Fig 1A). S. Typhimurium significantly194
increased VPAC1 mRNA expression by around 5 fold above expression in resting monocytes (P195
<0.05) but VPAC1 expression was not differentially expressed when monocytes were cultured196
with VIP (Fig 1B). After 6 and 24h pi, significantly more S. Typhimurium were recovered from197
infected monocytes which had been co-cultured with VIP, compared to infected monocytes198
without VIP (P <0.05) (Fig 1C).199
Following FACS analyses, we also detected a 50% increase in the immunoreactivity of VPAC1200
protein in the cytosol of monocytes after 6h pi with S. Typhimurium, which was highly201
significant (P <0.01) when compared to VPAC1 protein in the cytosol of monocytes incubated202
with VIP or uninfected monocytes (Fig 2A and C). FACS analysis also showed thatVPAC1203
protein was increased on the surface of monocytes infected with S. Typhimurium by around 30%204
and this increase was also significant (P <0.05) when compared to VPAC1 protein in the cytosol205
of monocytes incubated with VIP or uninfected monocytes (Fig 2B and D).206
Retrograde recycling of VPAC1 occurs following S. Typhimurium infection of monocytes207
Confocal microscopy showed that VPAC1 expression was similar in monocytes incubated with208
VIP to that in unstimulated monocytes (Fig 3A), this was low and was partially co-localized with209
the early endosome antigen 1 (EEA1) within the early/sorting endosome (SE). However, VPAC1210
immunofluorescent intensity was greatly increased and was strongly co-localized with EEA1211
following S. Typhimurium infection (Fig 3A). Following internalization of VPAC1 in the SE of212
S. typhimurium-infected monocytes, VPAC1 was trafficked from the SE to recycling endosomes213
(REs) associated with the TGN (retrograde trafficking). This was indicated by strong co-214
localization of VPAC1 with Rab11a (Fig 3B) and concomitant co-localisation of Rab11a with215
the trans-Golgi network (TGN), using TGN protein 46 (TGN46) as a marker Fig 3C).216
S. Typhimurium induces anterograde recycling of VPAC1 via Rab3a/CAM1.217
Further trafficking of VPAC1 in monocyte exosomes, following S. Typhimurium Infection, was218
indicated by strong co-localisation of VPAC1 with the membrane docking protein Rab3a (Fig219
4A) which was concomitantly co-localised with CAM1 (Fig 4B). Subsequent qPCR analysis220
showed that S. Typhimurium infection induced a >5 fold (P < 0.05) increase in both Rab3A and221
CAM1 above that measured in unstimulated monocytes or monocytes cultured with VIP (Fig222
4C). Addition of a CAM1 agonist (CALP1) to cell cultures significantly increased VPAC1223
mRNA expression in S. Typhimurium-infected monocytes (P <0.05), whereas addition of a224
CAM1 antagonist (W-7) significantly decreased VPAC1 mRNA expression (P <0.05) (Fig 4D).225
FACS analyses also indicated a causal association between CAM1 and VPAC1 protein226
expression. These showed that expression of VPAC1 protein on the surface of S. Typhimurium-227
infected monocytes was increased by CALP1 and decreased by W-7 (Fig 5G-I) compared to228
uninfected monocytes (Fig 5A-C) or monocytes cultured with VIP (Fig 5D-F) and in both cases229
these changes were significant (P <0.05). P- values were calculated by ANOVA analysis of230
mean expression detected for each experimental group (Shown in Fig 5K). A diagrammatic231
model of intracellular cycling of VPAC1, induced by S. Typhimurium infection, is shown in Fig232
5L.233
234
Discussion235
We show that S. Typhimurium increased expression of VPAC1 in human monocytes and this236
was associated with increased intracellular survival of the bacteria, when infected monocytes237
were co-cultured with VIP. This is in accordance with a study by Storka et al., (2013) (12) who238
reported a >30% increase in VPAC1 expression in monocytes isolated from human volunteers239
24h after infusion of lipopolysaccharide (LPS) from Escherichia coli and this was correlated240
with an increased concentration of VIP in plasma. However, at least some of this effect is241
probably due to increased monocyte survival (13, 19) but the effect is not merely due to LPS,242
which we found to induce lower levels of VPAC1 by both qPCR and FACS analyses compared243
to Salmonella infection (data not shown).244
Murine studies have indicated that the immunosuppressive effect of VIP occurs uniquely via245
VPAC1 (11) and that VIP/VPAC1 interaction regulates production of inflammatory mediators246
associated with mortality in sepsis (8), which may have evolved to protect the host. However,247
studies using viable Salmonella, rather than LPS have shown that VIP down-regulates248
inflammatory mediators and increases Salmonella survival in human monocytes (13, 19) and249
murine macrophages (20). We therefore hypothesised that S. Typhimurium actively utilises the250
VPAC1/VIP axis for its own survival advantage.251
We now show that S. Typhimurium not only increased VPAC1 mRNA and protein expression252
but also induced VPAC1 recycling to the cell membrane. The initial step in this process was253
internalization of VPAC1 into EEA-1-containing SE. EEA-1 is required for tethering, docking254
and fusion of the SE to Soluble NSF Attachment Protein Receptor (SNARE), which255
subsequently leads to endosomal shipment (21). A previous study has shown that internalisation256
and localisation of VPAC1 in the SE occurred in VPAC1 transinfected CHO cells, following257
culture with VIP (22). However, in this latter study, VPAC1 was not recycled back to the cell258
membrane and in accordance with this, we show that VIP did not increase VPAC1 expression on259
the cell membrane.260
Internalised proteins may be trafficked via the SE to late endosomes and lysosomes (which261
may prevent further recycling) or to the trans-Golgi network (TGN) (retrograde transport) which262
may sort the proteins into recycling endosomes (REs) for subsequent transport back to the cell263
membrane (anterograde transport) (23-24). This requires interaction with Ras-associated264
binding (Rab) proteins, which are small GTPases involved in intracellular trafficking of protein265
cargo from the SE to downstream endosomes, including the RE, and the docking of transport266
vesicles with membrane targets (25). In our study, S. Typhimurium-induced retrograde267
transport of VPAC1 was indicated by strong co-localisation of VPAC1 with Rab11a, one of the268
best studied markers of REs (26) and TGN protein 46 (TGN46). The TGN is the critical region269
on the Golgi apparatus, which collects and sorts newly synthesised proteins and proteins relayed270
to it from REs (27-28). Some bacterial toxins, such as Shiga toxin, produced by Shigella271
dysenteriae (29), HIV envelope protein (30) and the immunosuppressive HIV nef protein (31-32)272
are trafficked from the cell surface via retrograde transport. However, our study is the first to273
show that S. Typhimurium (or any other pathogen) induces retrograde transporting of VPAC1.274
The results we obtained also suggested that S. Typhimurium induced anterograde transport of275
VPAC1 via CAM1/Rab3a. The importance of Ca2+ in regulated exocytosis has been known for276
a number of years (33) and a study by MacKenzie et al., (34) also reported a positive correlation277
between Ca2+ concentration and VPAC1 density. Ca2+ binding by CAM1 forms Ca2+/CAM1278
complexes that bind to Rab3a, which subsequently causes switching of Rab3a from a GDP-279
bound (inactive form) to a GTP-bound (active) form (35). It is possible that the increase in280
CAM1 and Rab3a mRNA we show may increase calcium binding and active Rab3a and thus281
VPAC1 binding and transport to the cell membrane. Active Rab3a is a constituent protein in282
secretory vesicles within PC-12 cells and, in newly formed secretory vesicles associated with the283
TGN in pancreatic acinar cells (36) and is involved in the docking and exocytosis of secretory284
vesicles (37). Very little has been reported regarding Rab3a in immune cells but a study by Abu-285
Amer et al., (1999) (38) has shown that Rab3a expression is increased in murine bone marrow286
derived macrophages stimulated with LPS, although this was not studied in the context of287
VPAC1. We also show that S. Typhimurium (which contains LPS) significantly increased Rab3a288
and CAM1 mRNA expression in monocytes. Moreover, our results show a causal link between289
CAM1 and VPAC1 expression on the monocyte membrane. However, the effect of CAM1290
agonist or antagonist was not absolute, thus suggesting that other factors (possibly Rab3a itself)291
also directly affect VPAC1 expression on the monocyte surface.292
Only a fraction of newly synthesised VPAC1 become inserted into cell membranes, due to293
conformational misfolding (16) and although S. Typhimurium infection increased VPAC1294
mRNA expression, it is possible that S. Typhimurium-induced recycling of VPAC1 via295
retrograde/anterograde pathways overcomes low surface expression due to misfolding. This296
would facilitate greater interaction with the increased concentration of VIP in serum, as shown297
by Storka et al., (2013) (12).298
In conclusion, S. Typhimurium exploits the VPAC1/VIP axis to increase survival in human299
monocytes, this is achieved, at least in part, by retrograde and anterograde recycling of VPAC1300
via CAM1.301
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Figure Legends413
414
Table 1. Forward and reverse primers and probes used in PCR reactions.415
Forward and reverse primers and probes are shown for each gene analysed by PCR.416
417
Table 2. Primary and secondary antibodies used in confocal microscope analysis and flow418
cytometry.419
The type and concentration of primary and secondary antibodies, together with secondary420
antibody fluorophore conjugates, together with commercial suppliers, are shown.421
422
423
Figure 1. Increased survival of S. Typhimurium 4/74 in human monocytes co-cultured with424
VIP is associated with increased expression of VPAC1.425
Reverse transcription (rt) PCR showing constitutive and S. Typhimurium-induced expression of426
VPAC1 in monocytes after 6h post-infection (pi.). Comparison between VPAC1 expression is427
also shown with the reference gene β-actin, which is unchanged in both uninfected and infected 428
monocytes. (B) Quantitative PCR (qPCR) showing expression of VPAC1 after 6h pi in429
monocytes infected with S. Typhimurium or cultured with VIP (10-7 M). Fold changes are430
expressed in comparison with mRNA expression measured in unstimulated (control) monocytes,431
assigned an arbitrary expression value of 1. (C) Recovery of S. Typhimurium from monocytes432
cultured with or without VIP (10-7 M) at different times post-infection (pi). White bar = 2h pi,433
Grey bar = 6h pi, Black bar = 24h pi. Histograms (B and C) show means calculated from 5434
separate experiments performed in triplicate. Connecting bars show significant differences at P =435
0.05, error bars show standard deviation from the mean.436
437
Figure 2. S. Typhimurium 4/74 increases VPAC1 protein in the cytosol and cell membrane438
of human monocytes.439
VPAC1 expression is shown in representative FACS analyses of 5 independent experiments440
performed in (A) the cytoplasm (permeabilised) and (B) cell membrane (non-permeablised) at 6h441
pi. In all cases, lower left quadrants were set according to fluorescence expressed by monocytes442
incubated with secondary antibody only (control). Histograms show mean population sizes443
expressing VPAC1 after each treatment; permeabilised monocytes (C) and non-permeabilsed444
monocytes (D) calculated from 5 independent experiments performed in triplicate. Connecting445
bars show significant differences at P = 0.01-0.05, error bars show standard deviation from the446
mean.447
448
Figure 3. S. Typhimurium infection stimulates retrograde transported of VPAC1 from449
early/sorting endosome to Rab11a-containing recycling endosome localized with the trans-450
Golgi network in human monocytes.451
Confocal Laser Scanning Microscopy showing co-localization of VPAC1 with EEA1 and452
Rab11a in human monocytes, each panel shows a merged plane image 4 μm below the cell 453
surface. (A) Co-localization of VPAC1 immunofluorescence (green Alexa 488) with early454
endosome antigen 1 (red Alexa 647) (white arrows) with increased levels of VPAC1/EEA1455
association in S. Typhimurium infected monocytes at 6h pi.456
(B) Co-localisation of VPAC1 (green Alexa 488) with Rab11a (red Alexa 647) (white arrows) is457
shown only in S. Typhimurium infected cells and in (C) co-localisation of Rab11a (red Alexa458
647) with TGN46 (green Alexa 488) (white arrows) is shown only in S. Typhimurium infected459
cells. CLSM images shown are representative of 5 independent experiments performed in460
triplicate. Scale bar (bottom left) = 20 μm. 461
462
Figure 4. S. Typhimurium 4/74 induces packaging of VPAC1 within Rab3a/CAM1463
containing secretory vesicles for anterograde transport to the cell membrane of human464
monocytes.465
(A-B) Confocal Laser Scanning Microscopy showing co-localization of VPAC1 with Rab3a and466
CAM1. Each panel shows a merged plane image 4 μm below the cell surface. 467
(A) Co-localisation of VPAC1 (green Alexa 488) with Rab3a (red Alexa 647) (white arrows) in468
S. Typhimurium infected monocytes. (B) Co-localisation of CAM1 (green Alexa 488) with469
Rab3a (red Alexa 647) (white arrows) in S. Typhimurium infected monocytes. Images shown are470
representative of 5 independent experiments performed in triplicate. Scale bar (bottom left) = 20471
μm.  (C) qPCR showing increased expression of Rab3a and CAM1 mRNA in monocytes 6h pi 472
with S. Typhimurium. (D) qPCR showing fold changes in VPAC1 mRNA with or without CAM1473
agonist (CALP1) or antagonist (W-7). Each bar is a mean of 5 independent experiments474
performed in triplicate. White bar = Without agonist/antagonist, Black bar = + CALP1 (agonist),475
Grey bar = + W-1 (antagonist). Connecting bars show significant differences at P = 0.05, error476
bars show standard deviation from the mean. Fold changes are expressed as a comparison with477
mRNA expression measured in unstimulated (control) monocytes after 6h, assigned an arbitrary478
expression value of 1.479
480
Figure 5. CAM1 increases VPAC1 protein expression on the cell membrane of monocytes481
infected with S. Typhimurium 4/74.482
(A-J) FACS analysis showing VPAC1 expression on the monocyte membrane 6h pi with S.483
Typhimurium or monocytes cultured with VIP (10
-7
M) for 6h, with or without CAM1 agonist484
(CALP1; 20μg/ml) or CAM1 antagonist (W-7; 30 μg/ml). FACS analyses shown are 485
representative of experiments performed in triplicate on 5 separate occasions. Y-axes, SSC =486
Side scatter, X-axis = VPAC1 expression. Quantitative analysis of experimental means are487
shown in (K). Black bars = 2h post-treatment treatment/infection, White bars = 6h post-488
treatment/infection and Grey bars = 24h post-treatment/infection. Connecting bars show489
significant differences at P = 0.05, error bars show standard deviation from the mean.490
(L) Diagrammatic representation of S. Typhimurium induced trafficking of VPAC1 receptors. (1)491
S. Typhimurium invades monocyte. (2) VPAC1 is packages in the EEA1 positive sorting492
endosome (SE). (3) Retrograde transport of VPAC1 occurs via Rab11a positive recycling493
endosome (RE) which is associated with TGN46 on the Golgi apparatus. (4) Anterograde494
transport of VPAC1 occurs via Rab3a/CAM1 positive secretory vesicle (SV).495
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Gene Forward primer
(5’-3’)
Reverse primer
(3’-5’)
Probe
VPAC1
TCCGCCAGC
CACTCTATC
GCTCGAGCC
TGCACAATC
#19
Rab3a
AACGAGGAA
TCCTTCAATGCA
TGGGCATTGT
CCCATGAGTA
TGCAGGACTGGT
CCACCCAGATCA
CAM1
TGCATTCAGGGC
TGATTTATAGAG
AACAAGCTACAA
AATGCCAGAAAGA
CCCTTGGCTTCTC
CTTCTCCTACTCCCT
β-actin
CCAACCGCG
AGAAGATGA
CCAGAGGAGT
ACAGGGATAG
#64
Table 1. Askar et al
Receptor Primary antibody Conc.
(μg/ml)
Secondary antibody Conc.
(μg/ml)
VPAC1 Mouse anti-human IgG2a
(Abcam, Cambs, UK)
1 Rat anti-mouse IgG2a-Alexa 488
(Abcam, Camb, UK)
0.1
EEA1 Rabbit anti-human IgG
(Abcam, Camb, UK)
1 Donkey anti-rabbit IgG-Alexa 647
(Abcam, Camb, UK)
2
Rab3a Rabbit anti-human IgG
(Abcam, Camb, UK)
1 Donkey anti-rabbit IgG-Alexa 647
647 (Abcam, Camb, UK)
2
CAM1 Mouse anti-human IgG1
(Abcam, Camb, UK)
2 Rat anti-mouse IgG1-Alexa 488
(Invitrogen, Frederick, USA)
1
Rab11a Rabbit anti-human IgG
(Abcam, Camb, UK)
1 Donkey anti-rabbit IgG Alexa 647
647 (Abcam, Camb, UK)
2
TGN46 Mouse anti-human IgG1
(Abcam, Camb, UK)
5 Rat anti-mouse IgG1-Alexa 488
(Invitrogen, Frederick, USA)
1
Table 2. Askar et al
